Eli Lilly Opens an Individual-Patient Pathway for Unapproved Weight-Loss Drug Retatrutide, but This Is Not an Early Launch

A weight-loss drug that has not yet been approved for marketing is, in a rare move, opening a narrow pathway outside clinical trials. Eli Lilly confirmed that it will consider applications through an “expanded access” mechanism for a small number of patients who meet medical criteria and cannot participate in relevant trials; however, this is not an early drug-supply program with a waitlist open to the general patient population, nor does it mean regulators have confirmed the drug’s efficacy and safety.

Retatrutide is an experimental once-weekly injectable drug that acts simultaneously on the GIP, GLP-1, and glucagon receptors. This “triple agonist” design aims to combine effects including appetite regulation, blood glucose control, and energy expenditure. It is in late-stage clinical development and is also a highly anticipated candidate in the race to develop the next generation of obesity treatments.

The official ClinicalTrials.gov listing describes the arrangement as “pre-approval, single-patient expanded access,” with its status shown as available for application and Eli Lilly as the sponsor. The registration number is NCT07629401, and Eli Lilly’s internal protocol numbers 27979 and J1I-MC-Y001 are also listed. In other words, this mechanism centers on case-by-case review and is not a conventional clinical trial recruiting a cohort of patients at the same time.

The decision comes after Eli Lilly and the U.S. Food and Drug Administration previously agreed to allow one patient special access to retatrutide. According to STAT, other physicians subsequently sought the same opportunity for their own patients; Eli Lilly now says it will accept and evaluate a limited number of applications, creating a clearer application pathway for an arrangement that had previously been nearly an isolated case.

Expanded access generally requires that a patient have a serious or life-threatening disease, lack satisfactory approved treatments, and be unable to participate in a suitable clinical trial. The application must still be submitted by the treating physician and requires the drugmaker’s agreement to supply the drug, ethics review, and FDA authorization; the drugmaker may also decline based on supply, risk, or clinical-development considerations. Therefore, an obesity diagnosis alone or a desire to use a new drug early is not enough to guarantee access to retatrutide.

This narrow pathway also raises questions of fairness: which complications are sufficient to constitute an urgent need, how limited places should be allocated, and whether individual-patient use could affect trial recruitment all remain lacking in publicly available details. More importantly, expanded access is not a substitute for formal approval; until a full review is completed, retatrutide’s long-term benefits, rare adverse reactions, and appropriate patient populations still require clarification through more comprehensive data.